THE SURVIVAL RATE OF LC IS 15.5%.
THAT’S UNACCEPTABLE. WE’RE
HERE TO CHANGE THAT.

 

Spotlight on Cancer Diagnostic Tech: What is GE Clarient’s Multiplexing?

From rdmag.com

GE Reports: How else does multiplexing technology help with cancer diagnostics?

Dr. Burczak: Clarient has developed some molecular pathology tests that look at many different proteins. One such test, called Pulmotype, determines what type of lung cancer a patient has. One of the big problems with lung biopsies is the difficulty in obtaining enough tissue because the physician cannot remove a large section of lung. With the GE multiplexing technology, even with very small amounts of tissue, Clarient can run their whole Pulmotype test and get a complete analysis.

 

Trackback

 

3 Responses to “Spotlight on Cancer Diagnostic Tech: What is GE Clarient’s Multiplexing?”

Leave a Reply